Market Access European study shows inequality in access to new medicines PharmaphorumTrade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US's Most-Favoured Nation (MFN) policy.Read full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum Trade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US’s Most-Favoured Nation (MFN) policy. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Sanofi says drug for rare disease AATD tops standard careNext: UCB reports positive outcomes for bimekizumab in psoriatic arthritis Related Stories Market Access Deal finally unlocks NHS access to ITF’s Duchenne drug pharminent May 11, 2026 Market Access Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point pharminent May 5, 2026 Market Access Where Gross-to-net Pressure Actually Lives After Launch pharminent May 1, 2026
